<DOC>
	<DOCNO>NCT00142233</DOCNO>
	<brief_summary>This multi-centre randomise phase III , double blind , placebo control , parallel group , outpatient study patient diagnose hereditary pancreatitis idiopathic chronic pancreatitis . The hypothesis test 30 % reduction number day due pancreatitis 12.5 day per year le nine day per year treatment magnesium antioxidant cocktail call ANTOX . A total 240 patient randomise one three treatment group order compare pancreatic pain twelve month period .</brief_summary>
	<brief_title>EUROPAC-2 - Pain Treatment Hereditary Idiopathic Pancreatitis</brief_title>
	<detailed_description>Title : EUROPAC 2 trial investigate efficacy ANTOX ( vers ) 1.2 MGCT ( Magnesiocard ) treatment hereditary pancreatitis idiopathic chronic pancreatitis Study drug : ANTOX ( vers ) 1.2 MGCT ( Magnesiocard ) Intended indication : Hereditary pancreatitis idiopathic chronic pancreatitis Study design : A multi-centre , double blind , placebo-controlled , randomise , parallel group study Patient population : Patients hereditary pancreatitis idiopathic chronic pancreatitis Number patient : Total 240 patient three equal group Proposed number initial centre : two ( Greifswald , Germany Liverpool , UK ) . Duration dosing : 12 month Treatment group : Group one : Two ANTOX ( vers ) 1.2 tablet , three time daily , Antioxidant treatment : Daily : 300 µg organic selenium , 54000 IU beta carotene = 18 mg , 750 mg vitamin C , 540 IU vitamin E = 240 mg , 2700 mg methionine . Group two : Two Magnesium-L-Aspartate-hydrochloride ( MGCT ) ( Magnesiocard  2,5 mmol tablet three time day , total dose 15 mmol ( [ 365 mg/per day ] ) tablet . Group three : The number tablets Groups one two placebo instead active drug . Efficacy parameter : Primary : Pain ( number day pancreatic pain ) Secondary : Severity pain ; analgesic use pancreatic pain ; number day hospitalisation condition relate chronic pancreatitis ; quality life ; marker inflammatory response , antioxidant response , change urinary level magnesium , selenium , vitamin C activity pancreatitis pancreatic function . Safety parameter : Toxicity ; Adverse event</detailed_description>
	<mesh_term>Pancreatitis</mesh_term>
	<mesh_term>Pancreatitis , Chronic</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin E</mesh_term>
	<mesh_term>Beta Carotene</mesh_term>
	<mesh_term>Selenium</mesh_term>
	<mesh_term>Carotenoids</mesh_term>
	<criteria>1 . Patients must pancreatitis diagnose least one year . 2 . Patients must willing follow regularly least one year . 3 . Patients age 5 40 year age . 4 . Individuals must characteristic pancreatic pain either intermittent continuous . 1 . Patients consent involved trial , whose parent consent child involve . 2 . Patients guardians underage patient , learn disability cognitive sensory impairment would prevent adequate understanding study requirement . 3 . Patients treatment &lt; 3 month , currently receive treatment antioxidant magnesium tablet . 4 . Patients recent ( &lt; 3 month ) , currently receive treatment oral hypoglycaemics steroid treatment . 5 . Patients renal failure ( serum creatinine  200 g/l ) . 6 . Patients atrioventricularblock . 7 . Serum triglyceride level  1000 mg/dl . 8 . Patients age 5 year age 40 year . 9 . Patients dependent daily opiate analgesia ( morphine equivalent ) 12 month . 10 . Patients chronic hepatic failure , serious impairment pulmonary , cardiac , neurological , cerebral function . 11 . Patients participate another drug trial . 12 . Patients pregnant . 13 . Women childbearing age use contraception . 14 . Lactating mother . 15 . Any disorder would prevent adequate absorption active treatment .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>August 2005</verification_date>
	<keyword>EUROPAC 2 , ANTOX ( vers ) 1.2 , MGCT ( Magnesiocard ) Hereditary Pancreatitis , Idiopathic chronic pancreatitis .</keyword>
	<keyword>Hereditary Pancreatitis</keyword>
	<keyword>idiopathic chronic pancreatitis</keyword>
</DOC>